SCILEX HOLDING COMPANY

NASDAQ: SCLX (Scilex Holding Company)

Kemas kini terakhir: 07 Jul, 8:14PM

6.25

-0.11 (-1.73%)

Penutupan Terdahulu 6.36
Buka 6.25
Jumlah Dagangan 40,648
Purata Dagangan (3B) 147,265
Modal Pasaran 34,937,752
Harga / Jualan (P/S) 0.750
Harga / Buku (P/B) 28.85
Julat 52 Minggu
3.60 (-42%) — 73.50 (1076%)
Tarikh Pendapatan 12 Aug 2025
Margin Keuntungan -146.93%
Margin Operasi (TTM) -557.51%
EPS Cair (TTM) -15.27
Pertumbuhan Hasil Suku Tahunan (YOY) -54.00%
Nisbah Semasa (MRQ) 0.100
Aliran Tunai Operasi (OCF TTM) 15.96 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 42.76 M
Pulangan Atas Aset (ROA TTM) -69.26%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Bercampur Bercampur
Drug Manufacturers - General (Global) Bercampur Bercampur
Stok Scilex Holding Company Menurun Menaik

AISkor Stockmoo

-0.5
Konsensus Penganalisis -2.0
Aktiviti Orang Dalam NA
Volatiliti Harga -2.0
Purata Bergerak Teknikal 0.0
Osilator Teknikal 2.0
Purata -0.50

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
SCLX 35 M - - 28.85
AZN 226 B 2.13% 29.27 5.37
SNY 118 B 4.58% 16.37 1.35
AMGN 159 B 3.14% 26.89 25.84
GILD 136 B 2.85% 23.03 7.26
GRFS 6 B - 28.00 0.890

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Small Value
% Dimiliki oleh Orang Dalam 21.59%
% Dimiliki oleh Institusi 18.57%

Pemilikan

Nama Tarikh Syer Dipegang
E Fund Management Co., Ltd. 31 Mar 2025 31,431
Rafferty Asset Management, Llc 31 Mar 2025 17,717
Klp Kapitalforvaltning As 31 Mar 2025 10,212
23.4023.4019.2019.2015.0015.0010.8010.806.606.60Harga Sasaran MedianQ4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
23 Jun 2025 Pengumuman Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 t...
05 Jun 2025 Pengumuman Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal
16 May 2025 Pengumuman Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Intervention...
01 May 2025 Pengumuman Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventio...
30 Apr 2025 Pengumuman Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule
22 Apr 2025 Pengumuman Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 ...
16 Apr 2025 Pengumuman Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis
15 Apr 2025 Pengumuman Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®’s Acute Treatment of Migraine With or Without Aura ...
6.606.606.086.085.555.555.035.034.504.50Jun 25Jun 25Jun 26Jun 26Jun 27Jun 27Jun 30Jun 30Jul 1Jul 1Jul 2Jul 2Jul 3Jul 3Jul 7Jul 7

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.4000.4000.3000.3000.2000.2000.1000.1000.0000.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda